Department of Medicine  
Introduction   |   Research   |   Recent Publications   |   Patient Care   |   Faculty Profiles   |   Related Links   |   Give to Cardiology   |   Contact Us   |   Home


 
David L. Brown, MD, FACC, FAHA, FSCAI


 

David L. Brown, MD, FACC, FAHA, FSCAI
Professor of Medicine
Chief, Division of Cardiovascular Medicine

Division of Cardiovascular Medicine
SUNY-Stony Brook
Health Sciences Center T16-080
Stony Brook, NY 11794
Phone: 631-444-7515
Fax: 631-444-1054
E-mail: david.brown@stonybrook.edu

EDUCATION AND TRAINING

  • B.A. (cum laude), University of Texas, Austin, 1977
    M.D., Baylor College of Medicine, 1982
  • Internship, Internal Medicine, Baylor College of Medicine, Houston, TX, 1982-1983.
  • Resident, Internal Medicine, Baylor College of Medicine, Houston, TX,1983-1985.
    (Chief Medical Resident 1985-1986)
  • Fellowship, Hematology, University of California, San Francisco, 1986-1988.
  • Research Fellow, Platelet Biochemistry and Thrombosis Unit, Gladstone Foundation Laboratories for Cardiovascular Disease, Cardiovascular Research Institute, University of California, San Francisco, 1987-1990.
  • Fellow, Cardiology, University of California, San Francisco, 1990-1992.
  • Fellow, Interventional Cardiology, Cleveland Clinic Foundation, 1992-1993.

BOARD CERTIFICATION

  • American Board of Internal Medicine, 1986
  • American Board of Internal Medicine, Subspecialty of Cardiovascular Disease, 1991
  • American Board of Internal Medicine, Subspecialty of Interventional Cardiology, 2001 (Recertification 2005-2015)

AREAS OF CLINICAL EXPERTISE

  • Interventional Cardiology
  • Cardiac Intensive Care

CURRENT RESEARCH INTERESTS

  • Outcomes research in cardiovascular disease
  • Diagnosis and treatment of the vulnerable plaque
  • Volume-Outcome Relationship

SPECIAL ACCOMPLISHMENTS/RECENT PUBLICATIONS

  • Editor-in-Chief: Heart International, 2009
  • New York Magazine Best Doctors of New York, 2002-2008
  • Editorial Board: American Journal of Cardiology
  • Brown DL (Editor), Textbook of Cardiac Intensive Care, Philadelphia, W.B. Saunders Company, 1998. Second edition in progress.
  • Brown DL (Editor), Cardiovascular Plaque Rupture, New York, Marcel Dekker, 2002
  • Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina. Circulation 1995; 91:2125-2131.
  • Rill VL, Brown DL. The practice of coronary angioplasty in California in 1995: comparison to 1989 and impact of coronary stenting. Circulation 1999; 99: e12.
  • Sparano JA, Wolff AC, Brown D. Troponins for predicting cardotoxicity from cancer therapy. Lancet 2000;356:1947-1948.
  • Edep ME, Shirani J, Wolf P, Brown DL. Matrix metalloproteinase expression in non-rheumatic aortic stenosis. Cardiovasc Path 2000;9:281-286.
  • Vakili BA, Kaplan R, Brown DL. Operator and hospital volume-outcome relation in patients with acute myocardial infarction treated with primary angioplasty. Circulation 2001;104:2171-2176.
  • Vakili BA, Brown DL. Sex-based differences in early mortality of patients undergoing primary angioplasty for first acute myocardial infarction. Circulation 2001;104:3034-3038.
  • Brown DL. Deaths associated with glycoprotein IIb/IIIa inhibitor use. Heart 2003; 89: 535-537.
  • Vakili BA,Kaplan RC, Green SJ, Ravi KL, Sherman W, Sanborn TA, Slater JN, Brown DL. A propensity analysis of the impact of glycoprotein IIb/IIIa inhibitor use on in-hospital outcomes following percutaneous coronary interventions. Am J Cardiol 2003;91:946-950.
  • Levine GN, Kern MJ, Berger PB, Brown DL, Klein LW, Kereiakes DJ, Sanborn TA,Jacobs AK, for the American Heart Association Diagnostic and Interventional Cardiac Catheterization Committee.Management of patients undergoing percutaneous coronary revascularization. Ann Intern Med 2003;139:123-136.
  • Brown DL. Analysis of the institutional volume-outcome relationships for balloon angioplasty and stenting in the stent era in California. Am Heart J 2003; 146:1071-1076.
  • Brown DL, Desai K,Vakili BA, Nouneh C, Lee H-M,Golub LM. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial dose doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterio Thr Vasc Biol 2004; 24:733-738.
  • Wilson S, Vakili BA, Kaplan R, Green SJ, Ravi KL, Sherman W, Sanborn TA, Slater JN, Brown DL. Effect of diabetes mellitus on long-term mortality following contemporary percutaneous coronary intervention: analysis of 4284 cases. Diabetes Care 2004;27:1137-42.
  • Andraws R, Berger JS, Brown DL. Effects of antibiotic therapy on outcomes of patients with coronary artery disease: A meta-analysis of randomized controlled trials. JAMA.2005;293:2641-2647.
  • Moscucci M, Eagle KA, Share D, Smith D, DeFranco AC, O’Donnell M, Kline-Rogers E, Jani SM, Brown DL. Public reporting and case selection for percutaneous coronary interventions. J Am Coll Cardiol. 2005;45:1759-1765.
  • Berger JS, Roncaglioni CM, Avanzini F, Tognoni G,. Brown DL. Aspirin in the primary prevention of cardiovascular disease in women and men: a gender-specific meta-analysis. JAMA 2005; 295: 306-313. .
  • Piccini JP, Berger JS, Brown DL. Early sustained ventricular arrhythmias complicating acute myocardial infarction. Am J Med 2008;121:797-804.
  • Berger JS, Brown DL, Becker RC. Low-dose aspirin, cardiovascular events and all-cause mortality in patients with stable cardiovascular disease: a meta-analysis. Am J Med 2008;121: 43-49.
  • Alexander D, Ou F-S, Roe MT, Pollack Jr CV, Ohman EM, Cannon CP, Gibler WB, Fintel DJ, Peterson ED, Brown DL. Use of and in-hospital outcomes following acute clopidogrel therapy in non ST-segment elevation myocardial infarction: Results from CRUSADE. Am Heart J 2008; 156:606-612.
  • Wallace TW, Berger JS, Wang A, Velazquez EJ, Brown DL. Impact of left ventricular dysfunction on hospital mortality among patients undergoing elective percutaneous coronary intervention. Am J Cardiol. 2009;103:355-360.
  • Jeremias A, Kaul S, Gruberg L, Rosengart T, Brown DL. The impact of revascularization on mortality in patients with non-acute coronary artery disease. In press. Am J Med. 2009;122:152-161.
  • Berger JS, Brown, DL, Burke G, Oberman A, Kostis JB, Langer RD, Wong ND, Wassertheil-Smoller S. The effect of aspirin treatment and dose on all-cause mortality and cardiovascular events in postmenopausal women with stable cardiovascular disease: the Women’s Health Initiative Observational Study. Circulation: Cardiovascular Outcomes 2009;2:78-87.

© 2006 Stony Brook
Site design: Academic Web Pages